Business Context and Reporting Period
On July 20, 2026, Tempus AI, Inc. (Tempus) filed a Form 8-K to announce the entry into a definitive Agreement and Plan of Merger with Personalis, Inc. (Personalis). Under the agreement, Tempus will acquire Personalis in a transaction structured as a reorganization under Section 368(a) of the Internal Revenue Code. The transaction has been approved by the boards of directors of both companies, with the Personalis Board recommending the merger to its stockholders.
Key Financial Metrics and Transaction Terms
This filing details the terms of the merger rather than historical financial performance metrics such as revenue or cash flow. Key financial terms include:
- Consideration: Personalis stockholders will receive Tempus Class A Common Stock based on an Exchange Ratio. Tempus may elect to pay cash for up to 50% of the shares at a rate of $16.25 per share.
- Exchange Ratio: Fixed at 0.3356 if the Tempus Stock Price is $48.42 or lower. If the Tempus Stock Price exceeds $48.42, the ratio is calculated as $16.25 divided by the Tempus Stock Price.
- Termination Fees: A termination fee of approximately $76.8 million is payable by Personalis to Tempus under specific circumstances (e.g., adverse change recommendation). A reverse termination fee of approximately $76.8 million is payable by Tempus to Personalis if the deal fails due to regulatory restraints or if the closing does not occur by the Outside Date (April 20, 2027, subject to extensions).
- Equity Awards: In-the-money options and RSUs will generally be converted or assumed; out-of-the-money options will be cancelled without consideration.
Material Changes and Conditions
The filing does not report material changes to Tempus's historical financial results. The primary material event is the proposed acquisition. Closing is subject to several conditions, including:
- Approval by a majority of Personalis stockholders.
- Regulatory approvals, including the expiration of the HSR Act waiting period.
- Effectiveness of a Form S-4 registration statement.
- Absence of a Material Adverse Effect on either party.
- Personalis has the right to terminate if the Tempus Stock Price falls below $46.00 within two business days of the required closing date.
Outlook, Risks, and Management Commentary
Management intends for the transaction to qualify for tax-free treatment. The filing includes extensive forward-looking statements regarding the anticipated benefits and integration of the businesses. Key risks identified include:
- Failure to obtain stockholder or regulatory approvals.
- Disruption of ongoing business operations and retention of key personnel.
- Market price volatility of Tempus stock affecting the exchange ratio or triggering termination rights.
- Integration challenges and the ability to achieve anticipated synergies.
- Regulatory changes in healthcare and data privacy.
Investor Verification Checklist
- Verify the final Exchange Ratio based on the Tempus Stock Price at the time of closing.
- Confirm the outcome of the Personalis stockholder vote on the Merger Agreement.
- Monitor the status of regulatory approvals, specifically under the Hart-Scott-Rodino Antitrust Improvements Act.
- Review the definitive Proxy Statement/Prospectus (Form S-4) for detailed financial data and risk factors not fully elaborated in this 8-K.
- Track Tempus stock price relative to the $46.00 Lower Floor Price and $48.42 Floor Price thresholds.